Journal profile · Immunology and Microbiology-Immunology
Immune Network
ISSN 1598-2629 · eISSN 2092-6685 · Korean Association of Immunologists · South Korea
Immune Network: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 5.81; fully open access; APC about USD 1,000; median 63 days to acceptance (78 articles, last 24 months); 44 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Immune Network is published by Korean Association of Immunologists and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immune Cell Function and Interaction, Immunotherapy and Immune Responses and T-cell and B-cell Immunology, together about 44.3% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Since 2001, Immune Network (ISO abbreviation: Immune Netw.) is the official journal of the Korean Association of Immunologists (KAI). Immune Network publishes peer-reviewed articles that report novel findings in basic and clinical immunology. The journal publishes full-length articles, brief communications, reviews and technique reports. The journal is published online only in English and bimonthly on the last days of February, April, June, August, October, and December. All submissions, reviews, and decisions are processed on-line (https://immunenetwork.org). Also, full-text is freely available from the same web site (https://immunenetwork.org). This journal was supported by the Korean Federation of Science and Technology Societies Grant funded by the Korean Government(Ministry of Education). Immune Network is indexed/tracked/covered by Science Citation Index Expanded (SCIE), PubMed, PubMed Central, KoreaMed, Synapse, KoMCI, Crossref, SCOPUS, EMBASE and Google Scholar. ·
From the journal's Aims & Scope
Research area (LetPub): Immunology and Microbiology-Immunology
Editor-in-chief Chong-Kil LeePublisher website
Editorial board by country: 2 in mainland China (about 3%); most named South Korea 40, United States 16, Japan 5, Mainland China 2, Germany 2 (72 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immune Cell Function and InteractionImmunology and Microbiology18.7%
- Immunotherapy and Immune ResponsesImmunology and Microbiology13%
- T-cell and B-cell ImmunologyImmunology and Microbiology12.6%
- Immune Response and InflammationImmunology and Microbiology6.2%
- Monoclonal and Polyclonal Antibodies ResearchMedicine3.8%
- Immune cells in cancerImmunology and Microbiology3.7%
- CAR-T cell therapy researchMedicine3.7%
- Asthma and respiratory diseasesMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCPubMedPublisher website
Other: Google Scholar, Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.81LetPub ·
- CiteScore 2026-06
- 9.3LetPub ·
- SJR 2026-06
- 1.73LetPub ·
- SNIP 2026-06
- 1.16LetPub ·
- h-index
- 11LetPub ·
- h-index
- 69OpenAlex ·
- i10-index
- 498OpenAlex ·
- 2-year mean citedness
- 9.36OpenAlex ·
- Self-citation rate
- 5.1%LetPub ·
- Share of gold OA articles
- 99.22%LetPub ·
Volume
- Articles per year
- 42LetPub ·
Articles by year OpenAlex count · 1,047 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 35 | 35 | 45 |
| 2025 | 44 | 44 | 362 |
| 2024 | 45 | 45 | 754 |
| 2023 | 46 | 46 | 656 |
| 2022 | 51 | 51 | 1,166 |
| 2021 | 45 | 45 | 1,182 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
63 daysMedian, submission to acceptance · P25–P75 39 days – 99 days
- Acceptance to online
- median 28 days (78 articles)
- Submission to online
- median 89 days
- Sample
- 78 articles with submission and acceptance dates (79 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 1,000 / USD 1,200 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted12, with length limits
- brief communicationOriginal Articles Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. …main text ≤ 150 words · abstract ≤ 150 words · figures and tables ≤ 4
- brief communicationsBrief communications are short articles reporting findings of immediate impact.Length not stated
- correspondencesCorrespondences serve as a platform for the rapid exchange of opinions, views, or responses to previously published research.Length not stated
- editorialOriginal Articles Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. …figures and tables ≤ 1
- editorialsEditorials are invited perspectives aiming to provide new insights into active fields of immunological research.Length not stated
- letterOriginal Articles Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. …Length not stated
- opinionOriginal Articles Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. …Length not stated
- original articleOriginal Articles Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. …main text ≤ 200 words · abstract ≤ 200 words · figures and tables ≤ 7
- original articlesOriginal articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies.Length not stated
- perspectiveOriginal Articles Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. …Length not stated
- review articleOriginal Articles Original articles are full-length papers describing novel findings across all areas of immunology, including both basic and clinical studies. …main text ≤ 200 words · abstract ≤ 200 words · figures and tables ≤ 1
- review articlesReview articles are full-length papers aiming to provide new frameworks for recent findings, or balanced views of a field or topic.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use
Generative AI use allowed with disclosure; AI tools must not be listed as authors. Model summary
Authors may use generative AI tools to assist in preparing their manuscripts.
Source ↗Publisher website ·- Authorship 7. Author Contributions
ORCID ID of corresponding author required. Model summary
Enter all author contributions in the submission system during submission. The contributions of all authors must be described using the CRediT Taxonomy of author roles. To qualify for authorship, all contributors must meet at least one of the seven core contributions (conceptualization, methodology, software, validation, formal analysis, investigation, data curation), as well as at least one of th…
Source ↗Publisher website ·- Conflicts of interest 5. Conflicts of Interest
Conflicts of interest should be disclosed following the acknowledgements section. Disclosure of conflicts of interest must be followed by the guidelines described in Ethical Policy. 6. Artificial Intelligence (AI) Usage Disclosure • Authors may use generative AI tools to assist in preparing their manuscripts. • Authors remain fully responsible for the accuracy, originality, integrity, and scientif…
Source ↗Publisher website ·- License & copyright Copyright Transfer
All manuscripts are considered to be the property of KAI from the time of submission. Manuscripts published in Immune Network become the sole property of KAI with all copyrights reserved to KAI. The corresponding author, on behalf of all authors, must sign the Copyright Transfer Form, and return it to journal office, before publication. Authors reusing their own material do not need to contact KAI…
Source ↗Publisher website ·- Open access Open Access
Deposits all published articles into PMC since 2009. Model summary
Immune Network is an open access journal. Full-text and PDF are freely available from the journal homepage, https://immunenetwork.org. Publication Fees Publication fees have to be paid before publication. An invoice will be issued to the corresponding author upon acceptance. If the authors do not agree to pay, the Editorial Office may cancel the acceptance of the manuscript. Publication fees for i…
Source ↗Publisher website ·- Peer review 2. Peer Review Information
90 days to submit a revision. Model summary
1) Peer Review Process By submitting a manuscript to Immune Network, the authors agree to subject it to a confidential peer review process. Editors and reviewers are informed that the manuscript must be considered confidential. After a manuscript is received, it is assigned by Editor-in-Chief to a specific Deputy Editor, whose expertise is considered to be appropriate. The Deputy Editor selects at…
Source ↗Publisher website ·- Preprints Preprints
Preprints allowed at any time during peer review; not considered prior publication. Model summary
Immune Network encourages posting of preprints of primary research manuscripts on a community preprint servers such as bioRxiv. Preprints may be posted at any time during the peer review processes. Manuscripts posted to preprint server are not considered prior publication, nor are presentations of a work at a conference. Authors who post their work as a preprint should identify the preprint server…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Korean Association of Immunologists
- Country or region
- South Korea
- Language
- English
- ISSN
- 1598-2629
- Electronic ISSN
- 2092-6685
- Society / sponsor
- Korean Association of Immunologists
- Latest issue on the website
- Volume 26, Issue 4 (August 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
FAQ
Frequently asked questions about Immune Network
What CAS zone is Immune Network in?
In the 2025 upgraded edition of the CAS Journal Ranking, Immune Network is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Immune Network?
The latest impact factor listed by LetPub is 5.81; CiteScore 9.3, h-index 69.
How long does peer review take at Immune Network?
Based on the dates recorded on 78 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 63 days (interquartile range 39–99 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Immune Network based?
Of the 72 board members whose country the journal's board page names, 2 (about 3%) are in mainland China; the countries named most often are South Korea (40), United States (16) and Japan (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Immune Network?
According to LetPub and DOAJ records, Immune Network is indexed in SCIE and Scopus. The journal's website also lists Web of Science, PMC and PubMed; that list has not been checked against each database.
Is Immune Network open access, and what is the APC?
Immune Network is a fully open-access journal. APC about USD 1,000.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .